Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients With Sickle Cell Disease Using Altemia Capsules | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
learn more
view full news & events section

Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients With Sickle Cell Disease Using Altemia Capsules


Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the completion of enrollment of our clinical trial evaluating AltemiaTM, an oral therapy for pediatric patients with Sickle Cell Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT Trial is a double-blind, placebo-controlled, dose-finding, multi-center study to evaluate the efficacy and safety of AltemiaTM in pediatric patients aged 5-17 years old. This trial is conducted under US IND 125274.

“The completion of enrollment in this study represents an important milestone for SPCI and our lead program for SCA and SCD,” said Dr. Fred Sancilio, President and Chief Executive Officer of SPCI. “We are very encouraged by the high retention rate and adherence to treatment seen thus far in the study. This study will further our understanding of the impact of AltemiaTM on Sickle Cell Disease.”

https://www.onescdvoice.com/wp-content/uploads/2017/11/Sancilio-Pharmaceuticals-Company.jpg

expertly curated content related to this topic